Keywords: Shire, Lisdexamfetamine, Elvance, Tyvense, ADHA, EU, Regulatory approval, Vyvanse
Positive response from European regulatory procedure supports Shire's Elvanse for ADHD
Article | 18 December 2012
Ireland headquartered Shire (LSE: SHP) yesterday announced a positive outcome from the European Decentralized Procedure (DCP) for Elvanse (lisdexamfetamine dimesylate; ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
